Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line trial of nivolumab alone, nivolumab + ipilimumab, or nivolumab + platinum chemotherapy versus platinum chemotherapy in stage IV or recurrent non-small cell lung cancer
CTR20170340Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started May 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170340.